Nevro (NYSE:NVRO) said today that it agreed to bury the hatchet with Boston Scientific (NYSE:BSX) in their patent infringement spat over high-frequency spinal cord stimulation technology, sending its share prices up in mid-day trading. Last week a federal judge in California issued a mixed ruling in the case, finding that six claims in three of the Nevro patents are […]
Nevro Corp.
Boston Scientific delays Spectra WaveWriter trial data release
Boston Scientific (NYSE:BSX) is delayed the timeline for a clinical trial of its Spectra WaveWriter spinal cord stimulation device by nine months, chief medical officer Dr. Ian Meredith said yesterday, hard on the heels of a court decision involving SCS rival Nevro Corp. (NYSE:NVRO). Judge Vince Chhabria of the U.S. District Court for Northern California, who ruled earlier […]
Nevro shares plunge, rebound on court ruling in Boston Scientific spat
Anticipation over a court ruling in a patent spat between Nevro Corp. (NYSE:NVRO) and Boston Scientific (NYSE:BSX) sent NVRO shares plunging more than 26% yesterday, but after the actual ruling came out the stock surged some 24% today in pre-market trading. Judge Vince Chhabria of the U.S. District Court for Northern California, who ruled earlier this month […]
Nevro Q2 prelims top expectations on The Street
Nevro (NYSE:NVRO) today released preliminary second quarter results, expecting to post sales of $96.1 million, ahead of analyst’s expectations. The Redwood City, Calif.-based company said that of the $96.1 million, $79.9 million is expected to come from the US, with $16.2 million coming from international sales. Nevro updated its expectations for the full year as well, […]
Judge could deliver mixed results in Nevro’s patent spat with Boston Scientific
A federal judge in California last week tipped his hand in a tentative ruling, indicating that he may invalidate five of the seven Nevro patents at issue in the case but remained unclear about a number of other issues. Judge Vince Chhabria of the U.S. District Court for Northern California ruled July 5 that any […]
Judge sanctions Boston Scientific lawyers in Nevro patent row
A federal judge in California yesterday sanction lawyers for Boston Scientific (NYSE:BSX) in a patent infringement battle with neurostimulation rival Nevro (NYSE:NVRO). Back in October 2017, Judge Vince Chhabria of the U.S. District Court for Norther California found that, although the Nevro attorneys’ failure to correct a patent examiner’s misunderstanding of prior art was a little “sleazy,” it didn’t amount […]
Nevro dives on missed Q1 estimates
Share in Nevro Corp. (NYSE:NVRO) took a hit on Wall Street today as investors reacted to first-quarter sales and earnings numbers that missed the forecast. The Redwood City, Calif.-based neuromodulation company yesterday posted losses of -$17.5 million, or -59¢ per share, on sales of $87.6 million for the three months ended March 31, increasing its losses […]
Nevro wins FDA nod for MRI-conditional labeling on Senza SCS
Nevro (NYSE:NVRO) said yesterday that the FDA approved MRI-conditional labeling for its Senza spinal cord stimulation system designed to deliver HF10 therapy. The Redwood City, Calif.-based company said that with the labeling expansion, its devices are now cleared as MRI-safe in all its markets. The approval is retroactive, the company added, applying to all patients implanted with […]
Nevro misses with Q4 earnings, reups outlook
Nevro (NYSE:NVRO) yesterday reiterated its sales outlook for the rest of the year, saying it still expects to post a top line of $400 million to $410 million, but missed the consensus earnings forecast by a penny. The Redwood City, Calif.-based neurostimulation device maker posted losses of -$4.9 million, or -15¢ per share, on sales of $98.0 […]
Judge turns tables, chastises Boston Scientific lawyers in Nevro patent spat
Lawyers for Boston Scientific (NYSE:BSX) took their turns in the hot water as part of a patent infringement battle with neurostimulation rival Nevro (NYSE:NVRO). Back in October 2017, Judge Vince Chhabria of the U.S. District Court for Norther California found that, although the Nevro attorneys’ failure to correct a patent examiner’s misunderstanding of prior art was a little “sleazy,” […]
Abbott, Nevro tout spinal cord stimulation tech
Abbott (NYSE:ABT) and Nevro (NYSE:NVRO) touted their spinal cord stimulation technologies at the annual North American Neurological Society meeting in Las Vegas. Two-year data from Abbott’s 42-patient Sunburst study revealed that a majority of patients chose its BurstDR therapy when given the choice during the long-term follow-up period and that stimulation from BurstDR provided pain relief […]